3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Other hematologic neoplasm
1
Myeloid
1
Gastrointestinal
1
Dermatologic
1
CNS
1
Conditions
Glioblastoma
2
Pancreatic Neoplasms
1
Myelodysplastic Syndromes
1
Mesothelioma, Malignant
1
Melanoma
1
Leukemia, Myeloid, Acute
1
Central Nervous System Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
COVID-19
1
Interventions
Radiosurgery
22
Nivolumab
21
Ipilimumab
19
pembrolizumab
15
Temozolomide
11
dabrafenib
10
binimetinib
10
encorafenib
8
Cyclophosphamide
8
trametinib
7
Magnetic Resonance Spectroscopy
7
Bevacizumab
6
fludarabine
5
cobimetinib
5
Specimen Handling
5
CTLA-4 Antigen
5
fludarabine phosphate
3
aldesleukin
3
Vemurafenib
3
Thalidomide
3
Paclitaxel
3
Oxaliplatin
3
Interleukin-2
3
Gemcitabine
3
Drug Therapy
3
Carboplatin
3
130-nm albumin-bound paclitaxel
3
ulixertinib
2
tovorafenib
2
relatlimab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Melanoma
×
bemcentinib
×
CNS
×
Clear all
NCT06469138
2025-01-29
8479217
BerGenBio ASA
Phase 1
Completed
6 enrolled
17 charts